These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 1196428

  • 1. Vitiligo and malignant melanoma.
    Fodor J, Bodrogi I.
    Neoplasma; 1975; 22(4):445-8. PubMed ID: 1196428
    [Abstract] [Full Text] [Related]

  • 2. Autoimmunity as an aetiological factor in vitiligo.
    Rezaei N, Gavalas NG, Weetman AP, Kemp EH.
    J Eur Acad Dermatol Venereol; 2007 Aug; 21(7):865-76. PubMed ID: 17658994
    [Abstract] [Full Text] [Related]

  • 3. Autoimmune vitiligo: detection of antibodies to melanin-producing cells.
    Hertz KC, Gazze LA, Kirkpatrick CH, Katz SI.
    N Engl J Med; 1977 Sep 22; 297(12):634-7. PubMed ID: 331108
    [Abstract] [Full Text] [Related]

  • 4. [Malignant melanoma, leukoderma and vitiligo].
    Kraus L, Landthaler M.
    Z Hautkr; 1980 Feb 15; 55(4):218-31. PubMed ID: 6996365
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Characterization of antigens reacting with vitiligo and cytoplasmic melanoma antibodies].
    Presser HJ, Morenz J, Höfs T, Zugehör M, Kühne KH, Brödemann M.
    Dermatol Monatsschr; 1987 Feb 15; 173(8):441-5. PubMed ID: 3311840
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Detection of antibodies to melanoma cells in vitiligo by 125I-labeled SpA antibody binding assay].
    Mori N, Shimada K, Satoh N, Nagao S, Iijima S, Kanzaki T.
    Nihon Hifuka Gakkai Zasshi; 1986 Jul 15; 96(8):835-8. PubMed ID: 3784053
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
    Ram M, Shoenfeld Y.
    Ann N Y Acad Sci; 2007 Sep 15; 1110():410-25. PubMed ID: 17911456
    [Abstract] [Full Text] [Related]

  • 15. [Vitiligo and malignant melanoma (author's transl)].
    Hamm G, Fiedler H.
    Dermatol Monatsschr; 1979 Dec 15; 165(12):838-42. PubMed ID: 546664
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimelanoma immunity in vitiligo and melanoma patients.
    Juranic ZD, Stanojevic-Bakic N, Zizak Z, Babovic N, Radovic-Kovacevic V, Stanojkovic T, Dzodic R.
    Neoplasma; 2003 Dec 15; 50(4):305-9. PubMed ID: 12937846
    [Abstract] [Full Text] [Related]

  • 19. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
    Garbelli S, Mantovani S, Palermo B, Giachino C.
    Pigment Cell Res; 2005 Aug 15; 18(4):234-42. PubMed ID: 16029417
    [Abstract] [Full Text] [Related]

  • 20. Autoimmune aspects of vitiligo.
    Kemp EH, Waterman EA, Weetman AP.
    Autoimmunity; 2001 Aug 15; 34(1):65-77. PubMed ID: 11681494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.